Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

J&J Pharma Presents a Robust Pipeline and Outlines A New R&D Structure

This article was originally published in The Pink Sheet Daily

Executive Summary

In a wide-ranging presentation to Wall Street, the company highlights key new products in development and an R&D strategy built around five therapeutic areas.

You may also be interested in...



J&J Takes Leaner, But Stronger Business Approach With Management Consolidation

The health care giant is eliminating some management positions with more organizational announcements expected in coming weeks.

J&J Takes Leaner, But Stronger Business Approach With Management Consolidation

The health care giant is eliminating some management positions with more organizational announcements expected in coming weeks.

Sanofi-Aventis' New R&D Model Aims To Build A Network For Innovation

Anticipated reorganization seems to mimic previous actions by Big Pharma, with an emphasis on external collaboration and a move to smaller, independent groups..

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS069649

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel